allapinin

01/01/2002 - "Special feature of allapinin is its high efficacy for prevention of attacks of paroxysmal atrial fibrillation."
09/01/1990 - "In atrial fibrillation, allapinine was shown to enhance rhythm by 7% and to increase cardiac output (p less than 0.05), as well as to slightly lower mean blood pressure and peripheral vascular resistance at rest. "
09/01/1990 - "The long-term allapinine use yielded good results: its efficacy was proved to be approximately equal (63% and 60%) in patients with ventricular or supraventricular extrasystoles, respectively, but it was 77% in those with paroxysmal atrial fibrillation. "
01/01/2003 - "Allapinin proved to be highly effective: ventricular ectopic activity was suppressed in 71.4% patients, atrial tachycardia paroxysms were prevented in 72.7%, paroxysms of atrial fibrillation--in 77.8%. "
03/01/2016 - "Lappaconitine Hydrobromide (LH, allapinin) has been included by authors of National Guidelines on Diagnosis and Treatment of Atrial Fibrillation (AF), 2012 in the number of medications recommended for use in patients with AF for rhythm control. "

01/01/2014 - "[Efficiency and safety of allapinin in short- and long-term treatment of patients with normal heart and ventricular premature beats]."
07/01/1989 - "Allapinine was found to be beneficial both in ventricular and supraventricular premature beats. "
11/01/1988 - "[Comparative study of the effectiveness of allapinin in patients with frequent and stable extrasystole]."
01/01/1986 - "The results of the trial point to a potent and protracted antiarrhythmic effect of allapinin equally pronounced with both intravenous and oral administration to patients with ventricular and supraventricular premature beats. "
09/01/1990 - "The long-term allapinine use yielded good results: its efficacy was proved to be approximately equal (63% and 60%) in patients with ventricular or supraventricular extrasystoles, respectively, but it was 77% in those with paroxysmal atrial fibrillation. "

01/01/1988 - "Antiarrhythmic efficacy of allapinin was assessed in 15 patients with heart failure combined with ventricular arrhythmias (48 h ECG monitoring). "
09/01/1990 - "Physical exercise was not followed by an apparent additional aggravation of myocardial contractility, which makes allapinine preferable for long-term application to preserve sinus rhythm in patients without evident signs of heart failure."
01/01/1989 - "Allapinin after i.v. bolus infusion in a dose of 30 mg is relatively quickly eliminated from blood (in patients without congestive heart failure half-elimination period is 2.4 +/- 0.5 h and clearance is 79.0 +/- 8.9 l/h) which makes a good reason for its intravenous infusion according to the scheme "load dose + drop infusion". "
01/01/1989 - "Marked heart failure in patients with acute myocardial infarction compared to patients without heart failure results in reduced elimination rate, decreased clearance, significantly increased plasma allapinin concentration which should be taken in account when choosing the regime of drug infusion. "

09/01/1990 - "[Changes in systemic and intracardiac hemodynamics during bicycle ergometry in patients with fibrillation arrhythmia treated with allapinin before and after sinus rhythm recovery]."
09/01/1990 - "The authors summed up the practical experience gained in long-term maintenance treatment with allapinine, a new Soviet antiarrhythmic agent, given to 65 patients with various cardiac arrhythmias in the outpatient setting. "
10/01/1988 - "[Pharmacodynamics and the effectiveness of allapinin in patients with arrhythmia]."
09/01/1988 - "[The pharmacokinetics and pharmacodynamics of the new Soviet anti-arrhythmia preparation allapinin]."
01/01/1986 - "[Results of the clinical study of a new anti-arrhythmia preparation allapinin]."

01/01/2003 - "Antiarrhythmic activity of oral allapinin was studied in 64 patients with ischemic heart disease. "
11/01/1991 - "[Pharmacodynamics of allapinine during long-term infusion in patients with chronic ischemic heart disease and frequent ventricular extrasystole]."
01/01/2003 - "[Assessment of anti-arrhythmic efficacy of a domestic drug allapinin in patients with ischemic heart disease and cardiac arrhythmia]."
06/01/2021 - "The authors of this article have developed a new method of combined therapy of paroxysmal supraventricular tachyarrhythmias in patients with ischemic heart disease, including the use of allapinin and cardiac glycosides. "